[go: up one dir, main page]

EA200200284A1 - MESOPROGESTINES (PROGESTERONE RECEPTOR MODULATORS) AS A COMPONENT OF WOMEN'S CONTRACEPTIVES - Google Patents

MESOPROGESTINES (PROGESTERONE RECEPTOR MODULATORS) AS A COMPONENT OF WOMEN'S CONTRACEPTIVES

Info

Publication number
EA200200284A1
EA200200284A1 EA200200284A EA200200284A EA200200284A1 EA 200200284 A1 EA200200284 A1 EA 200200284A1 EA 200200284 A EA200200284 A EA 200200284A EA 200200284 A EA200200284 A EA 200200284A EA 200200284 A1 EA200200284 A1 EA 200200284A1
Authority
EA
Eurasian Patent Office
Prior art keywords
mesoprogestins
progesterone receptor
contraception
mesoprogestines
contraceptives
Prior art date
Application number
EA200200284A
Other languages
Russian (ru)
Other versions
EA006805B1 (en
Inventor
Кристоф Хвализц
Вальтер Эльгер
Герд Шуберт
Original Assignee
Йенафарм Гмбх Унд Ко. Кг
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Йенафарм Гмбх Унд Ко. Кг filed Critical Йенафарм Гмбх Унд Ко. Кг
Publication of EA200200284A1 publication Critical patent/EA200200284A1/en
Publication of EA006805B1 publication Critical patent/EA006805B1/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/567Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in position 17 alpha, e.g. mestranol, norethandrolone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18Feminine contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/24Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30Oestrogens

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Endocrinology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Reproductive Health (AREA)
  • Diabetes (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

В заявке описано применение мезопрогестинов для приготовления фармацевтического средства, предназначенного для женской контрацепции, фармацевтическая композиция, предназначенная для женской контрацепции, и способ осуществления женской контрацепции, предусматривающий введение эффективных количеств мезопрогестина женщине, нуждающейся в контрацепции. Мезопрогестин необязательно можно применять в сочетании с эстрогеном. Мезопрогестины в контексте настоящего описания определяются как соединения, обладающие как агонистической, так и антагонистической активностями в отношении рецептора прогестерона (PR) in vivo. Они стабилизируют функцию PR на уровне, который является промежуточным между агонистическим и антагонистическим уровнем. Соответствующие функциональные состояния не могут быть достигнуты с помощью прогестинов или антипрогестинов. Предпочтительными мезопрогестинами по изобретению являются J 867, J 912, J 956 и J 1042.Отчет о международном поиске был опубликован 2002.01.17.The application describes the use of mesoprogestins for the preparation of a pharmaceutical product intended for female contraception, a pharmaceutical composition intended for female contraception, and a method for performing female contraception, comprising administering effective amounts of mesoprogestin to a woman in need of contraception. Mesoprogestin can optionally be used in combination with estrogen. In the context of the present description, mesoprogestins are defined as compounds having both agonistic and antagonistic activities against the progesterone receptor (PR) in vivo. They stabilize PR function at a level that is intermediate between agonistic and antagonistic levels. The corresponding functional states cannot be achieved with progestins or antiprogestins. Preferred mesoprogestins of the invention are J 867, J 912, J 956 and J 1042. The international search report was published 2002.01.17.

EA200200284A 1999-08-31 2000-08-31 Mesoprogestins (progesterone receptor modulators) as a component of female contraceptives EA006805B1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US38613399A 1999-08-31 1999-08-31
PCT/IB2000/002053 WO2001026603A2 (en) 1999-08-31 2000-08-31 Mesoprogestins (progesterone receptor modulators) as a component of female contraceptives

Publications (2)

Publication Number Publication Date
EA200200284A1 true EA200200284A1 (en) 2002-10-31
EA006805B1 EA006805B1 (en) 2006-04-28

Family

ID=23524305

Family Applications (1)

Application Number Title Priority Date Filing Date
EA200200284A EA006805B1 (en) 1999-08-31 2000-08-31 Mesoprogestins (progesterone receptor modulators) as a component of female contraceptives

Country Status (28)

Country Link
EP (1) EP1605949A2 (en)
JP (1) JP2003511399A (en)
KR (1) KR20020038745A (en)
CN (1) CN1384748A (en)
AR (1) AR025455A1 (en)
AU (1) AU781835B2 (en)
BG (1) BG106441A (en)
BR (1) BR0013711A (en)
CA (1) CA2383650A1 (en)
CO (1) CO5190694A1 (en)
CZ (1) CZ2002707A3 (en)
EA (1) EA006805B1 (en)
EE (1) EE200200103A (en)
HR (1) HRP20020265A2 (en)
HU (1) HUP0202515A3 (en)
IL (1) IL148415A0 (en)
LT (1) LT5001B (en)
LV (1) LV12940B (en)
MX (1) MXPA02002186A (en)
NO (1) NO20020998L (en)
NZ (1) NZ517470A (en)
PE (1) PE20010579A1 (en)
PL (1) PL353994A1 (en)
SI (1) SI20853A (en)
SK (1) SK2982002A3 (en)
UA (1) UA77150C2 (en)
WO (1) WO2001026603A2 (en)
YU (1) YU13902A (en)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005539016A (en) * 2002-08-02 2005-12-22 シエーリング アクチエンゲゼルシャフト Progesterone receptor modulators with enhanced anti-gonadotropin activity for female fertility regulation and hormone replacement therapy
DE10236405A1 (en) 2002-08-02 2004-02-19 Schering Ag New 4-(3-oxo-estra-4,9-dien-11 beta-yl)-benzaldehyde oximes, are progesterone receptor modulators useful in female contraception, hormone replacement therapy and treatment of gynecological disorders
EP1624848A4 (en) * 2003-05-02 2009-02-25 Duramed Pharmaceuticals Inc Methods of hormornal treatment utilizing extended cycle contraceptive regimens
US20050215535A1 (en) * 2004-03-24 2005-09-29 Kristof Chwalisz Sequential SPRM/progestin treatment
MXPA06014579A (en) * 2004-07-07 2007-03-01 Wyeth Corp Cyclic progestin regimens and kits.
DE102005050729A1 (en) * 2005-10-19 2007-04-26 Schering Ag Method of preventive on-demand hormonal contraception
PT2419108T (en) 2009-04-14 2016-11-07 Hra Pharma Lab Method for on-demand contraception
CN110548034A (en) * 2019-07-12 2019-12-10 广州莎蔓生物科技有限公司 Pregnancy-blocking medicine

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2054271A (en) 1932-05-17 1936-09-15 Schering Kahlbaum Ag Production of crystallized hormone esters
DE699310C (en) 1936-11-20 1940-11-27 Chemische Ind Ges Process for the preparation of compounds of the estradiol type which are esterified in the 3-position
US2225419A (en) 1937-03-01 1940-12-17 Schering Corp Process for the conversion of 17-cisalcohols of the cyclopentanopolyhydrophenanthrene series into the corresponding 17-trans-alcohols
US2611773A (en) 1951-08-21 1952-09-23 Upjohn Co Estradiol 17-cyclopenetanepropionate
US2990414A (en) 1957-03-26 1961-06-27 Syntex Sa 17-undecenoate of estradiol
DE3337450A1 (en) 1983-10-12 1985-04-25 Schering AG, 1000 Berlin und 4709 Bergkamen PROSTAGLANDINE AND ANTIGESTAGE FOR PREGNANCY ABORT
ES2169030T3 (en) * 1987-09-24 2002-07-01 Jencap Res Ltd PACKAGING CONTAINERS CONTAINING STROGEN AND PROGESTINE.
US5439913A (en) 1992-05-12 1995-08-08 Schering Aktiengesellschaft Contraception method using competitive progesterone antagonists and novel compounds useful therein
US5516769A (en) 1993-02-19 1996-05-14 The Medical College Of Hampton Roads Method of inhibiting fertilization
DE4332283A1 (en) 1993-09-20 1995-04-13 Jenapharm Gmbh Novel 11-benzaldoximestradiene derivatives, processes for their preparation and medicaments containing these compounds
DE4332284C2 (en) * 1993-09-20 1997-05-28 Jenapharm Gmbh 11-Benzaldoxime-17beta-methoxy-17alpha-methoxymethyl-estradiene derivatives, process for their preparation and medicaments containing these compounds
DE4429397C2 (en) 1994-08-09 2003-11-20 Jenapharm Gmbh Estra-1,3,5 (10) -triene derivatives, processes for their preparation and pharmaceutical compositions containing these compounds
DE4447714C2 (en) 1994-08-09 1998-02-05 Jenapharm Gmbh Oestrogen compsn contg. 3-sulphamoyl:oxy-oestratriene cpd.
PT787002E (en) * 1994-10-24 2007-03-30 Schering Ag COMPETITIVE PROGESTERONE ANTAGONISTS FOR NEED-ORIENTED FEMALE FERTILITY CONTROL
US6040340A (en) * 1996-05-07 2000-03-21 Schering Aktiengesellschaft Implantation rates after in vitro fertilization, treatment of infertility and early pregnancy loss with a nitric oxide donor alone or in combination with progesterone, and a method for contraception with nitric oxide inhibitors
WO1997049407A1 (en) * 1996-06-25 1997-12-31 Akzo Nobel N.V. Progestogen-anti-progestogen regimens
WO1998005679A2 (en) * 1996-08-05 1998-02-12 Duke University Mixed agonists of the progesterone receptor and assays therefor
DE19809845A1 (en) * 1998-03-03 1999-09-09 Jenapharm Gmbh S-substituted 11beta-benzaldoxime-estra-4,9-diene-carbonic acid thiol esters, processes for their preparation and pharmaceutical preparations containing these compounds
HK1043788A1 (en) * 1999-05-04 2002-09-27 American Home Products Corporation Tetracyclic progesterone receptor modulator compounds and methods

Also Published As

Publication number Publication date
AU781835B2 (en) 2005-06-16
SI20853A (en) 2002-10-31
BR0013711A (en) 2002-05-07
KR20020038745A (en) 2002-05-23
BG106441A (en) 2002-09-30
YU13902A (en) 2006-01-16
LT2002035A (en) 2002-10-25
EE200200103A (en) 2003-04-15
IL148415A0 (en) 2002-09-12
EP1605949A2 (en) 2005-12-21
CZ2002707A3 (en) 2002-11-13
NZ517470A (en) 2004-03-26
NO20020998D0 (en) 2002-02-28
CA2383650A1 (en) 2001-04-19
MXPA02002186A (en) 2002-09-02
WO2001026603A3 (en) 2002-01-17
LT5001B (en) 2003-03-25
HUP0202515A3 (en) 2004-06-28
PE20010579A1 (en) 2001-06-04
LV12940B (en) 2003-06-20
WO2001026603A2 (en) 2001-04-19
AU3215001A (en) 2001-04-23
HRP20020265A2 (en) 2004-02-29
CN1384748A (en) 2002-12-11
PL353994A1 (en) 2003-12-15
NO20020998L (en) 2002-03-14
HUP0202515A2 (en) 2002-12-28
AR025455A1 (en) 2002-11-27
CO5190694A1 (en) 2002-08-29
EA006805B1 (en) 2006-04-28
UA77150C2 (en) 2006-11-15
SK2982002A3 (en) 2002-07-02
JP2003511399A (en) 2003-03-25

Similar Documents

Publication Publication Date Title
WO1995011013A3 (en) Combination of progesterone antagonists and anti-oestrogens with partial agonistic action for use in hormone-replacement therapy for peri- and post-menopausal women
AU3694901A (en) A parasiticidal formulation and a method of making this formulation
US5577514A (en) Condom
EA200000492A1 (en) ORAL CONTRACEPTIVES CONTAINING ANTIESTROGEN PLUS PROGESTINS
KR940005290A (en) Bioadhesive Therapeutic Compositions and Methods of Use
BR9714270A (en) Liquid skin cleansing composition
WO2002051363A3 (en) Absorbent articles with simplified compositions having good stability
BR0215380A (en) Pharmaceutical or nutraceutical micronized powder for immediate release and use thereof
UA37259C2 (en) Active substance for pharmaceutical compositions intended for treatment of dysfunctional metrorrhagia
EA200200284A1 (en) MESOPROGESTINES (PROGESTERONE RECEPTOR MODULATORS) AS A COMPONENT OF WOMEN'S CONTRACEPTIVES
EA200100828A1 (en) 16 HYDROXYETTRATRIENES AS ESTROGENS OF ELECTORAL ACTION
TNSN01076A1 (en) ASSOCIATIONS OF GROWTH HORMONE SECRETAGOGUES AND ANTIDEPRESSANTS, AND COMPOSITIONS CONTAINING THEM
YU14002A (en) Mesoprogestins (progesterone receptor modulators) for the treatment and prevention of benign hormone dependent gynecological disorders
BR0214332A (en) Method for providing a topical base composition for use in the preparation of a cosmetic composition, resealable cosmetic container, and anhydrous composition
EA200601089A1 (en) TRANSDERMAL DELIVERY OF HORMONES WITHOUT THE NEED TO USE AGENTS, STRENGTHENING PENETRATION
EP0247251B1 (en) Vaginal contraceptive
WO2003099322A3 (en) Il-11 derivatives and therapeutic uses thereof
EA200200285A1 (en) MESOPROGESTINES (MODELS OF PROGESTERONE RECEPTOR) AS A COMPONENT OF COMPOSITIONS FOR DEPENDENT HORMONAL THERAPY (HRT)
SE9201425D0 (en) METHOD AND MEANS FOR PREVENTING CONSTRICTION OF THE PUPIL IN THE EYE
JP4022675B2 (en) Antipruritic composition
SE8901149D0 (en) AGENTS FOR INDUCTION RESPECTIVE PREVENTION OF PUPILL CONSTRUCTION IN OEGAT
AU9028098A (en) Combinations of endometrial sparing progestins and endometrial atrophizing progestins with estrogens, in oral contraception
WO2001028578A3 (en) A PHARMACEUTICAL COMPOSITION CONTAINING pGLU-GLU-PRO-NH2 AND METHOD FOR TREATING DISEASES AND INJURIES TO THE BRAIN, SPINAL CORD AND RETINA USING SAME
BR0214334A (en) Method for providing a topical base composition for use in the preparation of a cosmetic composition, resealable cosmetic container, and anhydrous composition
WO1997033597A1 (en) An aphrodisiac for application to the sexual organs

Legal Events

Date Code Title Description
PC1A Registration of transfer to a eurasian application by force of assignment
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ KZ KG MD TJ TM

MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): BY RU